RM

RESERVE MEDS

RESERVED FOR YOU.

PATIENT ACCESS BRIEF

Lyfgenia in Nigeria

The NAFDAC named-patient coordination pathway — indicative 2026

RARE DISEASE · SEVERE SICKLE CELL DISEASE

The clinical situation

Lyfgenia (lovotibeglogene autotemcel, lovo-cel) is an FDA-approved autologous lentiviral-vector gene therapy for patients aged 12+ with sickle cell disease and a history of vaso-occlusive events. Manufactured by bluebird bio. Because lovo-cel is a one-time autologous cell therapy, it cannot be “imported” as a conventional drug — it requires patient travel to a qualified treatment centre abroad for apheresis, manufacture, conditioning, and infusion under a cross-border referral framework.

The pathway, 5 steps

1. **Consultation & haematology workup.** Treating haematologist confirms severe SCD phenotype, VOE history, organ-function clearance, and suitability for myeloablative conditioning.
2. **Qualified treatment centre identified.** Reserve Meds coordinates acceptance at a bluebird-authorised treatment centre (typically US or EU) and confirms slot availability.
3. **NAFDAC & Federal MoH referral documentation.** Cross-border referral package assembled: clinical rationale, centre acceptance letter, financing confirmation, and travel authorisation for patient and caregiver.
4. **Apheresis, manufacture & conditioning.** Stem-cell collection at the centre, 3–4 month vector manufacture, then busulfan conditioning and one-time infusion of modified cells.
5. **Post-infusion follow-up & repatriation.** Engraftment monitoring for 30–60 days on-site, then structured handoff back to the Nigerian haematology team with long-term registry follow-up.

Indicative economics

Reference US list-price range: USD 3.0–3.3M one-time product. Treatment-centre professional fees, conditioning, apheresis, hospitalisation, travel, and concierge coordination are incremental and typically add a material multiple. Full transparent quote at intake.

Indicative intake-to-infusion timing

10–16 weeks from complete referral package to one-time infusion, driven primarily by vector manufacture. Indicative — not guaranteed.

Reserve Meds's role

Centre access. Coordination with bluebird-authorised treatment centres and acceptance slot management. **Documentation.** Cross-border referral package for NAFDAC, Federal MoH, and receiving centre. **Travel & logistics.** Patient-and-caregiver travel, visa support, and on-site concierge during the 30–60 day engraftment window. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the treatment centre. All clinical decisions remain with the treating haematologist and the qualified treatment centre.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Lyfgenia × Nigeria first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemeds.com/access-guides/lyfgenia-nigeria.html

SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemeds.com · hello@reservemeds.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team